Phase 2 Safety Profile Overview
The Phase 2 retatrutide trial (Jastreboff et al., 2023, NEJM) collected comprehensive adverse event data across four active dose cohorts (1mg, 4mg, 8mg, 12mg) and placebo through 48 weeks. The overall safety profile is consistent with the GLP-1 receptor agonist class — gastrointestinal (GI) events dominated, particularly during dose escalation.
GI adverse events were predominantly mild-to-moderate in severity and occurred most frequently during the escalation phase. They generally reduced in intensity once participants reached their maintenance dose — a temporal pattern seen across all GLP-1 class compounds and attributed to receptor adaptation over time.
Phase 2 AE profile at a glance Most common class: gastrointestinal · Onset: primarily during escalation · Severity: predominantly mild-to-moderate · SAEs: low, not significantly different from placebo · Discontinuation due to AEs: 5–16% across dose cohorts
Gastrointestinal Adverse Events by Dose Cohort
GI adverse event rates from Phase 2 (Jastreboff 2023, NEJM). Rates represent participants experiencing each event at any point during the trial:
| Adverse event | Placebo | 1mg | 4mg | 8mg | 12mg |
|---|---|---|---|---|---|
| Nausea | 17% | 45% | 55% | 60% | 65% |
| Vomiting | 5% | 18% | 25% | 30% | 35% |
| Diarrhoea | 15% | 28% | 32% | 36% | 42% |
| Constipation | 12% | 18% | 20% | 22% | 26% |
| Decreased appetite | 8% | 32% | 42% | 48% | 52% |
| Dyspepsia / reflux | 6% | 12% | 15% | 17% | 19% |
Note: Figures are approximated from published Phase 2 results. Refer to Jastreboff et al., NEJM 2023 for primary data.
Nausea was the single most common adverse event across all active dose groups, increasing from ~45% at 1mg to ~65% at 12mg versus 17% placebo. The placebo rate establishes that a meaningful proportion of GI symptoms in GLP-1 trials reflects study participation effects rather than drug action alone.
Serious Adverse Events and Discontinuation Rates
Serious adverse events (SAEs) were uncommon in Phase 2. Rates were not significantly different from placebo, with no clear dose-response relationship for SAE frequency. Hepatic AEs, gallbladder events, and cardiovascular events occurred at low rates comparable to placebo.
Discontinuation due to adverse events followed a clear dose-dependent pattern:
| Dose cohort | Discontinuation due to AEs | Primary reason |
|---|---|---|
| Placebo | ~3% | — |
| 1mg | ~5% | GI adverse events |
| 4mg | ~8% | GI adverse events |
| 8mg | ~12% | GI adverse events (nausea, vomiting) |
| 12mg | ~16% | GI adverse events (nausea, vomiting) |
For comparison: semaglutide STEP 1 reported ~7% discontinuation at 2.4mg; tirzepatide SURMOUNT-1 reported ~4–7% depending on dose. Retatrutide's 12mg rate of ~16% is higher — consistent with the stronger pharmacological activity of triple versus single receptor agonism.
Dose-Related AE Pattern and Temporal Profile
A consistent temporal pattern emerged across all retatrutide dose cohorts: adverse events were most frequent during dose escalation and reduced substantially once participants reached maintenance dose. Key Phase 2 observations:
- The majority of GI AEs occurred within the first 12–16 weeks — corresponding to the active escalation period for higher-dose cohorts
- At the 24-week mark, GI AE rates had declined substantially across all cohorts relative to the escalation period
- The 12mg cohort's longer escalation window (reaching maintenance at week 21) extended the high-event period compared to lower-dose cohorts
- Participants who required dose holds showed broadly comparable final AE rates to those who advanced on schedule
Injection site reactions Reported across all cohorts at low rates. Typically mild: erythema, induration, pruritis. Rotating injection sites weekly minimises local tissue effects.
Managing GI Side Effects in Research Protocols
The Phase 2 protocol employed two primary management tools for GI adverse events:
- Dose hold: Pause the escalation schedule, remain at the current dose for an additional 4 weeks, then attempt escalation again. Holds do not constitute discontinuation.
- Dose reduction: Step back one dose level (e.g. 8mg to 4mg) for intolerable AEs. Re-escalate after tolerability is re-established.
Practical factors associated with GI AE reduction in GLP-1 class research:
- Reducing meal portion size relative to pre-protocol baseline, particularly in the first 8 weeks
- Avoiding high-fat meals immediately following injection
- Administering the weekly injection at a consistent time, not immediately before or after the largest meal of the day
- Maintaining adequate hydration to reduce nausea severity
- Not advancing dose steps during periods of concurrent illness
For the complete escalation schedule, see Retatrutide Dosage Protocol. For a cross-compound safety comparison, see Retatrutide vs Semaglutide.